PAGoDA: a Phase Ib/IIa trial combining the selective dual Trk/Fms kinAse inhibitor PLX-7486 with Gemcitabine as first or second-line treatment, in patients with locally advanced or metastatic pancreatic Ductal Adenocarcinoma (PDAC) and cancer related pain

Trial Profile

PAGoDA: a Phase Ib/IIa trial combining the selective dual Trk/Fms kinAse inhibitor PLX-7486 with Gemcitabine as first or second-line treatment, in patients with locally advanced or metastatic pancreatic Ductal Adenocarcinoma (PDAC) and cancer related pain

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs PLX 7486 (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms PAGoDA
  • Most Recent Events

    • 05 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top